Overview
- The U.S. International Trade Commission opened a combined modification and enforcement proceeding focused solely on Apple’s updated Blood Oxygen feature.
- Officials will examine whether Apple causes infringement when disputed functions occur through an Apple Watch paired with an iPhone.
- The proceeding follows Apple’s August rollout of a redesign that shifts viewing of blood-oxygen results to the iPhone after U.S. Customs approved the change.
- Masimo has sued U.S. Customs to challenge that approval, while Apple continues to contest prior ITC orders at the federal appeals court.
- In a separate California case, a federal jury found Apple infringed a Masimo patent and awarded $634 million, and Apple says it will appeal the verdict.